Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Studies from W.J. Urba and co-authors have provided new information about cancer vaccines
December 10th, 2008
"This phase I-II study evaluated the safety, clinical activity and immunogenicity of an immunotherapy developed from human prostate cancer cell lines (PC-3 and LNCaP) modified to secrete granulocyte-macrophage colony-stimulating factor. Patients with noncastrate prostate cancer (19) with biochemical (prostate specific antigen) recurrence following prostatectomy or radiation therapy and no radiological evidence of metastasis were enrolled in the study," investigators in the United States report. "Patients were injected with an initial dose of 5 X 10(8) cells followed by 12 biweekly administrations of 1 X 108 cells. The adverse event profile, prostate specific antigen...
Source: Vaccine Weekly (2008-12-10)
|
